Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials

References

• Lenartova A, Johannesen TB, Tjønnfjord GE. National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953–2012: a systematic analysis of population-based data. Cancer Med. 2016;5:3588–3595.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl. 5):78–84.
   PubMed Web of Science ®Google Scholar
• Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–215.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29:1602–1604.
   PubMed Web of Science ®Google Scholar
• Robak T, Stilgenbauer S, Tedeschi A. Front-line treatment of CLL in the era of novel agents. Cancer Treat Rev. 2017;53:70–78.
   PubMed Web of Science ®Google Scholar
• Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood. 2001;98:3050–3057.
   PubMed Web of Science ®Google Scholar
• Robak T, Robak P. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int Rev Immunol. 2013;32:358–376.
   PubMed Web of Science ®Google Scholar
• Coutré SE, Furman RR, Flinn IW, et al. Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Cancer Res. 2017;10:1–7.
   Google Scholar
• Brown JR, Byrd JC, Coutré SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–3397.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutré SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
   PubMed Web of Science ®Google Scholar
• Sanford DS, Wierda WG, Burger JA, et al. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk. 2015;15:385–391.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–211.
   PubMed Web of Science ®Google Scholar
• Jones J, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Hematol. 2017;4:e114–e126.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18:297–311.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Brown JR, Delgado J, et al. Updated analysis of overall survival in randomized phase III study of idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL. Blood. 2016;128:Abstract 231.
   Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Schwarzer G, Carpenter JR, Rücker G. Meta-Analysis with R. Springer, New York: Springer International Publishing; 2015.
   Google Scholar
• Peng RD. Reproducible research in computational science. Science. 2011;334:1226–1227.
   PubMed Web of Science ®Google Scholar
• Varma G, Johnson TP, Advani RH. Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. Clin Adv Hematol Oncol. 2016;14:543–554.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. University of York, UK: CRD; 2009.
   Google Scholar
• Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011;12:1204–1213.
   PubMed Web of Science ®Google Scholar
• Niederle N, Megdenberg D, Balleisen L, et al. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol. 2013;92:653–660.
   PubMed Web of Science ®Google Scholar
• Robak T, Warzocha K, Govind Babu K, et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2017;58:1084–1093.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. JCO. 2010;28:1756–1765.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Zelenetz AD, Gordon LI, et al. NCCN guidelines? insights: chronic lymphocytic leukemia/small lymphocytic leukemia, Version 1.2017: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2017;15:293–311.
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Cramer P, Goede V, et al. Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review. Ther Adv Hematol. 2017;8:197–205.
   PubMed Web of Science ®Google Scholar
• Waldron M, Winter A, Hill B. Pharmacokinetic and pharmacodynamic considerations in the treatment of chronic lymphocytic leukemia: ibrutinib, idelalisib, and venetoclax. Clin Pharmacokinet. 2017 [Mar 25]; DOI: 10.1007/s40262-017-0529-1.
   PubMedGoogle Scholar
• Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128:138–140.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Stingo F, Keating MJ, et al. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016;122:2505–2511.
   PubMed Web of Science ®Google Scholar
• Skarzynski M, Niemann CU, Lee YS, et al. Interactions between ibrutinib and anti-CD20 antibodies; competing effects on the outcome of combination therapy. Clin Cancer Res. 2016;22:86–95.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–1418.
   PubMed Web of Science ®Google Scholar
• Naggara O, Raymond J, Guilbert F, et al. The problem of subgroup analyses: an example from a trial on ruptured intracranial aneurysms. Am J Neuroradiol. 2011;32:633–636.
   PubMed Web of Science ®Google Scholar